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Abstract
Introduction
Hypertension and dyslipidemia often precede cardiovas-
cular disease. Lifestyle modifications help prevent these 
conditions, and referrals for women may be possible dur-
ing  reproductive  health  care  visits.  However,  screening 
recommendations vary, which may affect screening rates. 
The objectives of this systematic review were to 1) assess 
the  available  literature  on  the  effectiveness  of  lifestyle 
interventions,  2)  review  hypertension  and  dyslipidemia 
screening recommendations for consistency, and 3) report 
prevalence data for hypertension and dyslipidemia screen-
ing among women of reproductive age.
Methods
We conducted a systematic literature search (January 
1990-November  2010)  for  1)  randomized  controlled   
trials on the impact of lifestyle interventions on cardio-
vascular disease risk factors in women of reproductive 
age, 2) evidence-based guidelines on hypertension and 
dyslipidemia screening, and 3) population-based preva-
lence studies on hypertension or dyslipidemia screening 
or both.
Results
Twenty-one of 555 retrieved studies (4%) met our inclusion 
criteria. Lifestyle interventions improved lipid levels in 10 
of 18 studies and blood pressure in 4 of 9 studies. Most 
guidelines recommended hypertension screening at least 
every 2 years and dyslipidemia screening every 5 years, 
but recommendations for who should receive dyslipidemia 
screening varied. One study indicated that 82% of women 
of reproductive age received hypertension screening dur-
ing  the  preceding  year.  In  another  study,  only  49%  of 
women aged 20 to 45 years received recommended dyslip-
idemia screening. 
Conclusions
Lifestyle  interventions  may  offer  modest  benefits  for 
reducing  blood  pressure  and  lipids  in  this  population. 
Inconsistency  among  recommendations  for  dyslipidemia 
screening may contribute to low screening rates. Future 
studies should clarify predictors of and barriers to choles-
terol screening in this population.
Introduction
Cardiovascular disease (CVD) is the leading cause of death 
in women (1) and the third leading cause of death among 
women  of  reproductive  age  (defined  as  18-44  y  unless   
otherwise specified) (2). The prevalence of hypertension 
and dyslipidemia, 2 major CVD risk factors, is relatively 
high  among  women  of  reproductive  age.  During  2005 
through 2008, 8% of women aged 20 to 44 years had hyper-
tension or were taking hypertension medication (2), and 
11% had dyslipidemia (2). Although hypertension preva-
lence rates have remained stable during the last 10 years, 
approximately 40% of reproductive-aged adults (both men 
Cheryl L. Robbins, PhD; Patricia M. Dietz, DrPH; Jennifer Bombard, MSPH; Michelle Tregear, PhD; Steven M. 
Schmidt, PhD; Stephen J. Tregear, DPhil
  www.cdc.gov/pcd/issues/2011/nov/11_0029.htm • Centers for Disease Control and Prevention  1
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the 
Centers for Disease Control and Prevention.VOLUME 8: NO. 6
NOVEMBER 2011
2  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/nov/11_0029.htm
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position  
of the Centers for Disease Control and Prevention.
and women) with hypertension are unaware they have the 
condition (3).
Overall,  women  of  reproductive  age  are  not  generally 
considered to be at high risk for CVD, but identification 
of hypertension and dyslipidemia has reproductive health 
significance. For women of reproductive age with hyper-
tension,  combined  hormonal  contraceptive  methods  are 
generally  not  recommended  because  they  may  increase 
CVD risk. Additionally, hypertension during pregnancy is 
associated with adverse outcomes such as preeclampsia, 
placenta  abruption,  preterm  delivery,  low  birth  weight, 
and  infant  death  (4-7).  Dyslipidemia  is  associated  with 
polycystic  ovary  syndrome  (8),  the  most  common  endo-
crine disorder among women of reproductive age and a 
leading cause of infertility (9). Dyslipidemia during preg-
nancy may also have adverse effects on both the fetus and 
mother (10,11).
Because women of reproductive age are at risk of becom-
ing  pregnant  and  drug  therapy  may  pose  risks  to  the 
fetus,  lifestyle  modifications  are  often  the  first  line  of 
treatment for hypertension or dyslipidemia. The effective-
ness of lifestyle interventions such as exercise and diet 
on  cardiovascular  outcomes  is  well  established  for  men 
and older women (12-18), but their effects on women of 
reproductive age are largely unknown. Reviewing hyper-
tension and dyslipidemia screening recommendations for 
consistency between guidelines and understanding screen-
ing prevalence for women of reproductive age may clarify 
intervention referral opportunities. To our knowledge, no 
published reports have compared screening guidelines as 
they pertain to this population. 
The  primary  objective  of  this  systematic  review  was  to 
evaluate the evidence from randomized controlled trials 
(RCTs) that have investigated the effects of lifestyle inter-
ventions  on  hypertension,  dyslipidemia,  or  CVD  illness 
and death in this population. Secondary objectives were to 
review hypertension and dyslipidemia recommendations 
for consistency and to report the prevalence of screening 
among women of reproductive age.
Methods
Data sources
Using  electronic  bibliographic  databases  (PubMed/
MEDLINE,  Cochrane  Database  of  Systematic  Reviews, 
and US National Guideline Clearinghouse), we conducted 
electronic  searches  on  lifestyle  interventions,  nation-
al  hypertension  and  dyslipidemia  screening  guidelines, 
and screening prevalence for women of reproductive age 
from January 1, 1990, through November 18, 2010. We 
also  searched  for  relevant  guidelines  published  by  the 
American College of Obstetricians and Gynecologists. To 
conduct  the  search,  we  used  a  combination  of  free  text 
terms and concepts derived from the National Library of 
Medicine’s medical subject headings (Table 1). We applied 
additional  filter  options  (English  language  and  human 
studies) and related search features in iterative fashion to 
identify all relevant literature. In addition, we reviewed 
reference  lists  from  retrieved  articles  and  searched  the 
grey literature, which consists of reports, studies, articles, 
and  monographs  produced  by  federal  and  local  govern-
ment  agencies,  private  organizations,  and  educational 
institutions.
Study selection
Lifestyle interventions
Two researchers (S.T., M.T.) searched the literature inde-
pendently  and  selected  studies  on  the  basis  of  a  priori 
inclusion criteria. We used researcher agreement to rec-
oncile questions that arose about eligibility. We found no 
systematic reviews or meta-analyses of the effect of life-
style interventions on CVD illness or death that focused 
on women of reproductive age or that parsed data to allow 
such analysis. Therefore, we used the following a priori 
inclusion criteria to identify individual studies: 1) RCTs or 
randomized crossover study designs; 2) enrolled 10 or more 
women of reproductive age or whose sample included sub-
group analyses for women of reproductive age, or both; 3) 
full-length article; 4) outcomes of blood pressure, lipids, or 
CVD illness or death, or all; 5) diet or exercise intervention 
or both; and 6) published in the English language. Twenty-
one of 555 studies (3.8%) met all a priori selection criteria 
and addressed 1 or more relevant outcomes (Figure).
Screening recommendations
Of  particular  interest  to  this  review  was  an  examina-
tion  of  guidelines  likely  to  be  in  current  use.  As  such, 
we  focused  on  national-level  US-based  guidelines.  We 
examined evidence-based guidelines produced under the 
auspices of medical specialty associations, relevant pro-
fessional societies, and federal government agencies that 
had been reviewed, revised, or developed within the last VOLUME 8: NO. 6
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5 years (2005-2010), with the exception of 2 older seminal 
guidelines (the Joint National Committee on Prevention, 
Detection,  Evaluation,  and  Treatment  of  High  Blood 
Pressure [JNC 7] and the Adult Treatment Panel III cho-
lesterol guidelines, both sponsored by the National Heart, 
Lung, and Blood Institute [NHLBI]), which continue to 
be referenced by other current guidelines. To be included 
in our assessment, a guideline had to meet the evidence-
based  criteria  required  for  acceptance  in  the  National 
Guideline Clearinghouse (www.guideline.gov/about/inclu-
sion-criteria.aspx).
Screening prevalence
To  describe  current  hypertension  and  dyslipidemia 
screening practices in the target population, we focused 
our  searches  on  studies  emanating  from  large  popula-
tion-based  surveys  in  the  United  States,  including  the 
Behavioral  Risk  Factors  Surveillance  System  (BRFSS), 
the  Medical  Expenditure  Panel  Survey  (MEPS),  the 
National Ambulatory Medical Care Survey (NAMCS), the 
National Health Interview Survey (NHIS), the National 
Health  and  Nutrition  Examination  Survey  (NHANES), 
and the National Survey of Family Growth (NSFG).
Data extraction
We extracted data from included studies into comprehen-
sive evidence tables to facilitate assessment of the quality 
of the individual studies. For the purposes of this report, 
we present details on the study setting and population, 
intervention, results (significant changes in outcomes in 
intervention groups relative to controls), and study quality 
from lifestyle intervention articles. We present included 
studies  in  descending  chronological  order,  identified  by 
first author and year (Tables 2, 3, and 4). We used a vali-
dated instrument designed to evaluate the internal valid-
ity of controlled studies to assess the quality of each of the 
studies. ECRI Institute (Plymouth Meeting, Pennsylvania) 
developed the instrument, which is available on request 
from the authors (19). We made no attempt to analyze or 
synthesize the findings quantitatively because of the large 
variation in the interventions assessed. Instead, we sum-
marize the data qualitatively.
We  extracted  the  following  elements  from  hypertension 
and dyslipidemia guidelines: year, target population, rec-
ommended screening interval for all healthy and at-risk 
women of reproductive age, risk factors, and diagnostic 
criteria  (Table  5).  Lastly,  we  describe  screening  preva-
lence estimates for hypertension and dyslipidemia among 
women of reproductive age obtained from 2 studies that 
used population-based surveys.
Results
Lifestyle interventions
Of 555 retrieved references, we identified 21 studies that 
met  our  inclusion  criteria,  including  diet  interventions 
(n  =  3),  exercise  interventions  (n  =  13),  and  combined 
diet  and  exercise  interventions  (n  =  5).  Eighteen  stud-
ies examined the effect of an intervention on lipid levels, 
9  examined  blood  pressure  measures,  and  none  focused 
on CVD illness or death. Study follow-up ranged from 6 
weeks to 2 years. After reading the abstracts or the entire 
text, we excluded approximately 96% of the studies (534 
of 555) largely because data precluded separate analyses 
of women of reproductive age (78%) (Figure). Additionally, 
14% were excluded because our targeted outcomes were 
not addressed, and 8% were not RCTs or crossover study 
designs.  We  summarized  findings  from  the  trials  that 
investigated the effect of diet, exercise, and combined diet 
and exercise interventions on systolic blood pressure (SBP), 
diastolic blood pressure (DBP), total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), low-density lipo-
protein cholesterol (LDL-C), and triglycerides (TG).
Diet alone
We  summarized  data  from  3  low-  to  moderate-quality, 
randomized crossover studies (20-22) involving 86 women 
Figure. Selection of individual studies examining the effects of lifestyle inter-
ventions on hypertension, dyslipidemia, and cardiovascular disease illness 
and death among adult women of reproductive age.  Abbreviations: RCT, 
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of reproductive age that met our inclusion criteria (Table 
2). All examined lipid levels and 1 also examined blood 
pressure measures (21). Study settings included Australia 
and the United States, and all studies compared low-fat 
to  higher-fat  diets  and  reported  reduced  mean  values 
in  TC  (10.8-30.2  mg/dL),  LDL-C  (8.7-26.3  mg/dL),  and   
HDL-C (3.4-10.1 mg/dL) for participants who followed low-
fat diets. The study that examined blood pressure reported 
significant mean reductions in DBP (4.4 mm Hg) and arte-
rial pressure (3.8 mm Hg) but not SBP for participants 
following a low-fat diet.
Exercise alone
Thirteen  RCTs  (12  moderate  quality,  1  high  quality) 
involved 482 women of reproductive age (Table 3). Exercise 
modes included resistance and endurance training, walk-
ing, running, and aerobics; study duration ranged from 6 
to 40 weeks with varying intensities. Ten RCTs (23-32) 
examined lipids and 5 examined blood pressure (23,31,33-
35).  All  lipid  RCTs  evaluated  TC,  LDL-C,  HDL-C,  and 
TG except 1, which did not examine LDL-C (32). Study 
settings  were  Brazil,  Ireland,  Nigeria,  Turkey,  and  the 
United States.
Findings were mixed for the impact of exercise on lipid 
levels among women of reproductive age. In 3 of 10 trials, 
significant reductions in mean TC levels were found among 
those who received resistance training (12.8-16.3) or aero-
bics (28.2-39.8), compared with controls (25,27,29). Among 
2  recent  studies  that  examined  TC,  resistance  training 
significantly reduced mean TC (12.8 mg/dL) compared with 
controls, but stair climbing did not (24,29). The other 7 stud-
ies that examined TC demonstrated no significant impact 
from exercise (23,24,26,28,30-32). Two of 9 trials examin-
ing LDL-C showed that stair climbing (24) and resistance 
training (29) led to significant mean improvements among 
women of reproductive age (6.6 and 13.9 mg/dL, respec-
tively).  However,  7  studies  demonstrated  no  significant 
changes in LDL-C resulting from exercise (23,25-28,30,31). 
Only 1 study in 10 examining HDL-C demonstrated that 
exercise had a positive effect; it showed a mean increase 
of  6.5  mg/dL  for  step  aerobics  (25).  Another  study  sug-
gested undesirable effects of exercise on HDL-C (30), and 
8 trials demonstrated no significant alterations to HDL-C 
(23,24,26-29,31-32). None of the RCTs demonstrated sig-
nificant changes in TG in response to exercise.
Only 1 of the 5 trials examining blood pressure found an 
impact of exercise (35). That RCT showed continuous and 
interval aerobic training reduced SBP 10.8 to 12.4 mm 
Hg and DBP 2.5 to 2.6 mm Hg. None of the other RCTs 
demonstrated significant changes in blood pressure due to 
exercise.
Combined diet and exercise interventions
Five RCTs (1 low quality, 3 moderate quality, 1 high qual-
ity) representing 443 women of reproductive age (Table 4) 
examined TC, HDL-C, and TG; 3 examined LDL-C (36-38); 
and 3 examined blood pressure (38-40). Interventions var-
ied in duration, ranging from 14 weeks to 2 years. Study 
settings  were  Canada,  Finland,  Italy,  and  the  United 
States. The high-quality RCT was the most recent study, 
had  the  largest  sample  (120  obese  women  of  reproduc-
tive  age),  the  longest  intervention  period,  and  provided 
monthly sessions with a nutritionist and exercise trainer 
for the first year and bimonthly sessions in the second 
year (39). Interventions tested in the other RCTs included 
weight-reduction  diets  coupled  with  walking  and  group 
education (40) or with aerobics or resistance training (36); 
and aerobic exercise with low-fat diet and group education 
(38) or with fish diet (37).
Only 1 US RCT (38) found significant protective differ-
ences among the intervention groups relative to controls 
for TC and LDL-C reporting mean decreases in TC for the 
diet plus exercise group (10.8 mg/dL) and diet only (15.1 
mg/dL), and in LDL-C for both intervention groups (11.2 
and 10.9 mg/dL, respectively). One RCT focusing on obese 
women  reported  a  8.0  mg/dL  mean  increase  in  HDL-C 
among the intervention group (39). Four RCTs showed no 
effect of diet and exercise on HDL-C (36-38,40).
Three  RCTs  (37-39)  found  significant  mean  TG  reduc-
tions  (1.8-19.0  mg/dL)  among  intervention  groups.  The 
other 2 studies demonstrated no significant changes in TG 
(36,40).
Two studies (38,39) reported significant mean decreases in 
SBP (3.0-4.1 mm Hg) and DBP (2.0-3.0 mm Hg) among the 
intervention groups relative to controls. The other study 
that examined blood pressure demonstrated no significant 
changes as a result of diet and exercise (40).
Current recommendations for hypertension and dyslipid-
emia screening and lifestyle modifications
Seven  national  US  guidelines  containing  recommenda-
tions  for  hypertension  and  dyslipidemia  screening  were VOLUME 8: NO. 6
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identified  (Table  5).  The  guidelines  for  hypertension 
screening intervals and diagnostic criteria among women 
of reproductive age were generally consistent. Less agree-
ment was observed between guidelines in the criteria for 
diagnosing dyslipidemia and cholesterol screening recom-
mendations for women of reproductive age.
Five of the guidelines explicitly or by deferral to the NHLBI 
JNC7 guidelines (41) recommend hypertension screening 
every 2 years for adult women with optimal blood pres-
sure (<120/80 mm Hg) and more frequently for those who 
have  prehypertension  or  have  other  risk  factors  (41-46) 
(Table 5). Guidelines differ with regard to age at which 
hypertension screening should begin. The guidelines also 
vary in definitions of at-risk populations, but the following 
risk factors are consistent across guidelines: smoking, dia-
betes, obesity, physical inactivity, older age (>65 years for 
women), and having a personal or family history of prema-
ture CVD, hypertension, or dyslipidemia (<65 y for women 
and  <55  y  for  men).  The  American  Heart  Association 
(AHA) also addresses pregnancy conditions and other gen-
der-related comorbidities that identify women at risk (43). 
All organizations recommend that a series of standardized 
blood pressure measurements be taken over multiple visits 
before a diagnosis of hypertension is made, but there are 
nuanced differences between guidelines.
Lifestyle modifications, in particular exercise and weight 
reduction,  were  universally  recommended  by  all  guide-
lines  as  an  integral  part  of  CVD  prevention  and  as 
first-line treatment for milder forms of hypertension. In   
addition, most recommend smoking cessation, maintain-
ing a healthy diet rich in fruits and vegetables, and reduc-
ing alcohol and sodium intake.
National  cholesterol  guidelines  concur  that  women  at 
increased risk of coronary heart disease (CHD) should be 
screened for dyslipidemia. However, only AHA (43) and 
NHLBI  Adult  Treatment  Program  III  (48)  recommend 
screening  women  of  reproductive  age  (≥20  y)  who  are 
not at increased risk. Increased risk is generally defined 
by the presence of 1 or more of the following: diabetes, 
previous  personal  history  of  CHD  or  noncoronary  ath-
erosclerosis, a family history of premature CVD, current 
tobacco use, hypertension, or obesity. Screening frequency 
recommendations  are  similar,  generally  every  5  years, 
with shorter intervals for women whose lipid levels are 
close  to  warranting  therapy,  and  longer  intervals  for 
those not at increased risk if they have repeatedly had 
normal lipid levels. Most organizations recommend that 
a full lipid profile be obtained and that lipid screening be 
performed after a fast of 9 to 12 hours. However, there is 
some disagreement between guidelines about the need for 
fasting blood levels and the value of including triglycerides 
as a part of the initial tests (49). Furthermore, consensus 
about diagnostic criteria for dyslipidemia is lacking (Table 
5). Most guidelines recommend the same CVD risk reduc-
tion  lifestyle  modifications  for  cholesterol  management 
as mentioned previously for hypertension, except sodium 
reduction. Additionally, they emphasize high-fiber, low-fat 
diets.
Screening prevalence
We  identified  only  2  hypertension  and  dyslipidemia 
screening prevalence studies that used population-based 
data and included women of reproductive age. The sole 
report that examined hypertension screening rates among 
women of reproductive age (defined as 14-44 y) was based 
on 1988 NSFG data (50) and estimated annual hyperten-
sion  screening  within  the  preceding  year  to  be  82.3%. 
Predictors  of  hypertension  screening  among  women  of 
reproductive  age  in  that  report  included  having  had  a 
family planning visit in the previous 12 months, current or 
recent pregnancy, history of hypertension, older age, black 
race, and higher education or income (50). Only 1 study 
reported  cholesterol  screening  rates  among  women  of 
reproductive age, and it used 1999-2006 National Health 
and Nutrition Examination Survey (NHANES) data (51). 
That study reported 49% of women aged 20 to 45 years 
with no CHD risk factors received cholesterol screening 
within the preceding 5 years. Screening rates were 52% 
among women with 1 risk factor and 69% among those 
with CHD or CHD equivalent risk.
Discussion
Limited conclusions can be drawn about lifestyle interven-
tions in women of reproductive age because of the small 
number of included RCTs, the heterogeneity of interven-
tions examined, and the lack of consistent findings across 
studies.  Lifestyle  interventions  improved  dyslipidemia 
in 10 of 18 studies and hypertension in 4 of 9 studies. 
Stronger benefit was seen on levels of TC and LDL-C than 
on HDL-C or TG. Improvements in systolic blood pressure 
were seen in 3 of 9 studies that examined blood pressure 
changes. Diastolic blood pressure improved in 4 of 9 stud-
ies. Follow-up tended to be short-term (1-2 y), and most 
samples comprised healthy women of reproductive age.VOLUME 8: NO. 6
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Our assessment of the effectiveness of lifestyle interven-
tion  is  consistent  with  reviews  conducted  on  low-risk 
populations. A systematic review of lifestyle interventions 
among  healthy  adult  men  and  women  also  concluded 
that  lifestyle  interventions  offered  marginal  short-term 
benefit on blood pressure and, to a lesser degree, lipids 
(52).  Two  meta-analyses  examined  the  effect  of  aerobic 
exercise on blood pressure and found modest reductions 
among  normotensive,  mostly  older  women  (13,53).  The 
effects  of  lifestyle  interventions  on  lipids  appear  to  be 
strongest for LDL-C and TC and weaker for any benefit to   
HDL-C  or  TG,  consistent  with  similar  investigations 
(14,54). Previous reports indicated mixed findings regard-
ing  the  effect  of  exercise  on  TG  and  HDL-C  levels; 
improvements were reported for physically inactive sub-
jects primarily. Indeed, that was the case for the studies in 
which we found improvements in TG and HDL-C (38,39). 
Finally, exercise duration may be the most important pre-
dictor of change to HDL-C (55,56); the 2 studies reporting 
improvements in TG and HDL-C levels had the longest 
intervention duration (1-2 y).
The review of guidelines revealed that diagnostic criteria 
and  screening  recommendations  for  dyslipidemia  vary. 
Optimal  screening  tests  include  measurement  of  total 
and HDL-C levels or apolipoproteins without fasting and 
without  regard  to  triglycerides  (49).  Updated  NHLBI 
guidelines  for  hypertension  and  dyslipidemia  screening 
are anticipated in 2012.
We found only 1 study that examined prevalence of hyper-
tension screening and another for dyslipidemia screening 
among women of reproductive age. One study reported 82% 
of women of reproductive age received hypertension screen-
ing within the preceding year (50), which is higher than 
a current estimate of 75% screened (according to unpub-
lished  National  Health  Interview  Survey  [NHIS]  data 
analyses, women aged 14-44 y, 2008). However, nearly 90% 
of women of reproductive age get hypertension screening 
within the recommended interval of every 2 years (NHIS 
data analyses, 2008). Kuklina et al also reported that 49% 
to 69% of women aged 20 to 45 years had their cholesterol 
checked in the previous 5 years (51), which is consistent 
with estimates from 2008 NHIS unpublished analyses for 
the same population (64%). The lack of consensus among 
dyslipidemia screening guidelines may be the reason for 
lower screening rates in this population.
Few studies provide detailed examination of hypertension 
and dyslipidemia screening prevalence among women of 
reproductive age. Perhaps this gap in the literature exists 
because young people tend to be healthy and the age gradi-
ent is marked in these conditions, so women of reproduc-
tive age have not been considered a target for screening 
surveillance. However, identification of high-risk subpopu-
lations  and  clarification  of  screening  recommendations 
may prevent the onset of hypertension, dyslipidemia, and 
other chronic conditions such as diabetes among those at 
increased risk for CVD.
Substantial  body  of  evidence  establishes  that  diet  and 
exercise  improve  hypertension  and  dyslipidemia,  but 
that literature is predominantly based on studies of men 
and older women. Individual study samples included in 
this review may lack the power to detect the benefits of 
lifestyle  interventions  among  healthy  populations.  For 
example, pooled results among RCTs that enrolled healthy 
older women detected significant effects between aerobic 
exercise and blood pressure, although the individual RCT 
findings were not significant (53). Pooling studies in meta-
analyses can add the needed statistical power to detect 
modest short-term benefits of lifestyle interventions, but 
not enough studies are focused on women of reproductive 
age to do this.
Women of reproductive age are a population in need of 
CVD screening and early intervention. Lifestyle modifica-
tions are appropriate initial therapies for most patients 
and may reduce CVD risk through mechanisms other than 
lowering LDL-C or blood pressure, such as through smok-
ing  cessation,  weight  reduction,  and  increased  physical 
activity (48). Moreover, a dose-response effect of physical 
activity on CHD risk suggests that higher intensity exer-
cise conveys greater benefit (57-59).
To our knowledge, this is the first published systematic 
review  of  RCTs  examining  the  effects  of  lifestyle  inter-
ventions  on  hypertension,  dyslipidemia,  or  CVD  among 
women of reproductive age. Its strengths include a review 
of the grey literature, report of study flow, and assessment 
of the quality of included RCTs. The geographic breadth 
of included RCTs spanned Africa, Asia, Europe, Oceania, 
and North and South America. Studies from Europe and 
North America were most prevalent; thus, results are gen-
erally representative of women of reproductive age from 
those regions. However, racial composition was addressed 
in  only  one-third  of  the  studies  (20,22,28,29,31,33,34), 
and  only  5  included  minority  women  (20,22,31,33,35). 
Given racial differences in hypertension and dyslipidemia 
screening  (50,60,61)  and  the  need  to  explore  lifestyle   VOLUME 8: NO. 6
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interventions’  benefits  in  high-risk  subpopulations  of 
women of reproductive age, future RCTs should recruit 
sufficient numbers of at-risk women of reproductive age, 
including African American and obese women. The main 
limitation of this review is the possibility of missed stud-
ies. We did not search non–English-language literature, 
and it is possible that RCTs have been published in other 
languages. We also may have missed potentially relevant 
studies that are not indexed in PubMed.
Given the reproductive health importance of identifying 
hypertension or dyslipidemia among women of reproduc-
tive  age,  surveillance  of  hypertension  and  dyslipidemia 
screening in this population is needed. Lifestyle interven-
tions may offer modest short-term benefits for reducing 
blood pressure or lipids among healthy women of repro-
ductive age that may lead to larger long-term benefits. 
Further  research  is  needed  to  clarify  predictors  of  and 
barriers to cholesterol screening in this population and to 
investigate the long-term benefits of lifestyle interventions 
for women of reproductive age.
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Tables
Table 1. Medical Subject Headings and Free-Text Search Terms Used in Electronic Searches
Terms Medical Subject Headings Free-Text
Disease-specific–related 
terms
Hypertension 
Hypertension/epidemiology/*prevention and control
Dyslipidemia*
Dyslipidemia*/epidemiology/*prevention and control
Hyperlipidemia*
Hyperlipidemia*/epidemiology/*prevention and control
Hypercholesterolemia
Cholesterol, LDL
Cholesterol, HDL
Cardiovascular disease*
Cardiovascular disease*/epidemiology/*prevention and control
Complications
Blood pressure, high 
Hyperlipemia
Hyperlipidemia
Lipemia
Lipidemia
Lipid disorders
Cholesterol
Low-density lipoprotein cholesterol
High-density lipoprotein cholesterol
Triglycerides
Adverse events
Adverse effects
Screening and treatment-
related terms
Mass screening 
Exercise
Diet
Utilization
Therapy
Screening 
Screening trends
Exercise
Physical activity
Diet
Lipid analysis
Treatment
Disease management
Disease prevention
Other Cross-sectional survey 
Health surveys
Review
Meta-analysis
Guideline
NHANES 
NHIS
BRFSS
MEPS
NAMCS
Population survey
Systematic review
Meta-analysis
Clinical practice guideline
Evidence-based guidelines
Standards
 
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; NHANES, National Health and Nutrition Examination Survey; NHIS, National Health 
Interview Survey; BRFSS, Behavioral Risk Factor Surveillance System; MEPS, Medical Expenditure Panel Survey; NAMCS, National Ambulatory Medical Care 
Survey. Asterisk (*) indicates wildcard in search.VOLUME 8: NO. 6
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Table 2. Selected Characteristics of Randomized Controlled Trials Examining Cardiovascular Effects of Diet
Study, Setting, and 
Qualitya Study Populationb Intervention Results
Gerhard et al 2000 (20) 
Academic: Oregon Health 
Sciences University
Portland, Oregon, United 
States
Moderate
22 healthy white and African 
American premenopausal 
women aged 18- y living 
in the Portland area who 
participated in a previous 
study
Randomized crossover design assignment to 
diet order 
Intervention — Low- to high-fat/cholesterol 
diet and high- to low-fat/cholesterol diet
Protocol — Follow randomly assigned order of 
diets. Start first diet x  wks; -wk washout 
period; follow other diet for  wks
Low-fat and cholesterol diets were associ-
ated with 
1.  decreased TC
2.  decreased HDL-C
3.  decreased LDL-C
.  increased TG
White women (n = 9) had higher VLDL-C cho-
lesterol concentrations and TG than African 
American women (n = 13). Otherwise, no 
racial differences were noted.
Small sample sizes may have impaired ability 
to detect differences.
Pellizzer et al 1999 (21) 
Hospital: Austin Hospital
Victoria, Australia
Low
2 healthy, nonsmoking, 
premenopausal women 
aged 18- y in 20% of 
ideal body weight
Randomized, crossover design assignment to 
1 of 2 diets 
Intervention — 1st: Low in total and saturated 
fat (2%) and cholesterol; 2nd: High in total 
and saturated fat (0%) and cholesterol
Protocol — Follow randomly assigned order of 
diets. Start first diet, follow for 2 wks; 2-wk 
washout; Follow other diet for 2 wks
Low-fat diets associated with 
1.  decreased DBP
2.  decreased TC
3.  decreased HDL-C
.  decreased LDL-C
.  no significant change in SBP
6.  weight did not change significantly
Ginsberg et al 1998 (22) 
Multicenter trials: 
Columbia University, 
Pennington Biomedical 
Research Center, 
Pennsylvania State 
University, University of 
Minnesota, United States
Moderate
39 healthy, normolipidemic, 
premenopausal women 
recruited from  research 
centers; mean age, 31 y
Randomized, crossover design 
Intervention — Diet A: Average American diet 
with 3% fat, including 16% SFA; diet B: Step 
1 diet with 30% fat including 9% SFA; diet C: 
Low-SFA diet with 26% fat including % SFA
Protocol — Randomly assigned a diet 
sequence that includes each diet: ABC, ACB, 
BAC, BCA, CAB, or CBA
Assigned diets were followed for 8 wks, fol-
lowed by - to 6-wk washout between diets, 
and next diet
Relative to average American diet, Step 1 
and Low-SFA diets associated with 
1.  decreased TC
2.  decreased HDL-C
3.  decreased LDL-C
.  no significant change in TG
 
Abbreviations: TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; VLDL-C, very low-
density lipoprotein cholesterol; DBP, diastolic blood pressure; SBP, systolic blood pressure; SFA, saturated fatty acids. 
a Quality was defined as ratings based on ECRI Institute 2-item validated instrument (19). 
b Number of subjects limited to those who completed the study.VOLUME 8: NO. 6
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Table 3. Selected Characteristics of Randomized Controlled Trials Examining Cardiovascular Effects of Exercise 
Study, Setting, and Qualitya Study Populationb Intervention Results
Ciolac et al 2010 (23) 
Brazil
Moderate
 healthy female college students 
Mean age by group:
Aerobic interval training = 2. y; 
continuous exercise training = 26.6 y; 
control = 2.3 y
Intervention, n = 16; control, n = 12
Intervention. Five min warm up, 1 
min of calisthenics, and either aerobic 
interval training (AIT, n = 16) or contin-
uous exercise training (CET, n = 16) for 
0 min for 3 times/wk for 16 weeks 
Intensity. AIT = 0%-90% max ventila-
tion oxygen uptake (VO2MAX)
CET = 60%-0% VO2MAX
Relative to controls, interventions asso-
ciated with 
1.  no significant change in TC
2.  no significant change in LDL-C
3.  no significant change in HDL-C
.  no significant change in TG
.  no significant change in SBP
6.  no significant change in DBP
Boreham et al 200 (2) 
Northern Ireland, UK
High
1 sedentary, but otherwise healthy, 
young female college students 
Mean age, 18.8 y
Intervention, n = 8; control, n = 
Intervention. Stair-climbing program  
times/wk for 8 wks 
Intensity. Progressive starting with 2 
sets (199 stairs) at 90 steps/min and 
working up to  sets
Relative to controls, interventions asso-
ciated with: 
1.  decreased LDL-C
2.  no significant change in TC
3.  no significant change in HDL-C
.  no significant change in TG
Kin Isler et al 2001 (2) 
Ankara, Turkey
Moderate
 sedentary female college student 
volunteers 
Mean age by group: Step aerobics = 
21.9 y; aerobic dancing = 20.2 y; con-
trol = 21.9 y
Intervention, n = 30; control, n = 1
Intervention. Step aerobics (n = 1) or 
aerobic dancing (n = 1) for   min, 3 
times/wk for 8 wks
Intensity. Sixty to 0% heart rate 
reserve
Relative to controls, both interventions 
associated with 
1.  decreased TC
2.  no significant change in TG
3.  no significant change in LDL-C
Relative to controls, step aerobics 
associated with increased HDL-C
LeMura et al 2000 (26) 
Pennsylvania, United States
Moderate
 college-aged, nonsmoking female 
students with no regular physical activ-
ity for  mo before study, and taking 
no medications known to alter lipid 
metabolism 
Mean age = 20. y
Intervention, n = 33; control, n = 12
Intervention. Resistance training (n = 
11), aerobic training (n = 10), or cross 
training (n = 12) for 3 times/wk for 
16 wks
Intensity. Resistance = Nautilus 3 
times per wk; aerobic = 3 times per 
wk; cross-training = aerobics 2 times/
wk and Nautilus 2 times/wk
Control. No training during 16 wks.
Relative to controls, interventions asso-
ciated with 
1.  no significant change in TC
2.  no significant change in LDL-C
3.  no significant change in HDL-C
.  no significant change in TG
 
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. 
a Quality ratings based on ECRI Institute 2-item validated instrument (20). 
b Number of subjects limited to those who completed the study. 
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Study, Setting, and Qualitya Study Populationb Intervention Results
Prabhakaran et al 1999 
(2) 
Virginia, United States
Moderate
2 sedentary, premenopausal healthy 
women recruited by campus newspa-
per and word of mouth 
Mean age by group: resistance training, 
28.0 y; control, 26.0 y
Intervention, n = 12; control, n = 12
Intervention. Supervised, intensive, 
resistance exercise training sessions 
-0 min/d, 3 d/wk for 1 wks 
Control. Nonexercising
Relative to controls, intervention asso-
ciated with 
1.  decreased TC
2.  no significant change in LDL-C
3.  no significant change in HDL-C
.  no significant change in TG
.  no significant change in body mass
Duey et al 1998 (33) 
Alabama, United States
Moderate
2 sedentary African American women 
Mean age by group: intervention, 23.6 
y; control, 22.2 y
Intervention, n = 16; control, n = 9
Intervention. Endurance exercise train-
ing sessions  20 min/d (plus warm-up 
and cool-down), 3 d/week for 6 wks 
Intensity. Weeks 1-2: 60% peak oxy-
gen uptake (VO2peak); weeks 3-: 6% 
VO2peak; weeks -6: 0% VO2peak
Control. Usual diet and physical activity
Relative to controls, intervention asso-
ciated with 
1.  no significant change in SBP
2.  no significant change in DBP
Santiago et al 199 (28) 
Minnesota, United States
Moderate
2 mostly white, healthy female volun-
teers aged 22-0 y, nonsmokers, not 
pregnant, sedentary, body mass index 
<31 kg/m2 
Intervention, n = 16; control, n = 11
Intervention. Brisk treadmill walking for 
3 miles,   d/wk for 0 wks 
Intensity. 2% maximal heart rate
Control. Sedentary
Relative to controls, intervention asso-
ciated with 
1.  no significant change in HDL-C
2.  no significant change in LDL-C
3.  no significant change in TC
.  no significant change in TG
.  no significant change in body com-
position
Boyden et al 1993 (29) 
Arizona, United States
Moderate
88 white, healthy female volunteers 
aged 28-39 y, smoked ≤10 cigarettes/
d, inactive, not overweight or obese 
Intervention, n = 6; control, n= 2
Intervention. Resistance exercising for 
1 hour, 3 d/wk for  mos 
Intensity. Load major muscle groups in 
the arms, legs, trunk, and lower back
Control. Inactive
Relative to controls, intervention asso-
ciated with 
1.  decreased LDL-C
2.  decreased TC
3.  no significant change in HDL-C
.  no significant change in TG
 
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. 
a Quality ratings based on ECRI Institute 2-item validated instrument (20). 
b Number of subjects limited to those who completed the study. 
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Study, Setting, and Qualitya Study Populationb Intervention Results
Hinkleman et al 1993 (30) 
California, United States
Moderate
36 premenopausal female volunteers 
aged 2- y, not presently exercis-
ing or dieting, 10%-0% overweight, 
nonsmokers, no history of alcohol or 
drug abuse 
Intervention, n = 18; control, n = 18
Intervention. Walking  min,  d/wk 
for 1 wks 
Intensity.  Sixty percent heart rate
Control. Non-exercising
Relative to controls, intervention asso-
ciated with 
1.  no significant change in LDL-C
2.  no significant change in TC
3.  no significant change in TG
.  decreased HDL-C
.  significant change in body weight
6.  no significant change in body fat
Katz et al 1992 (3) 
Ohio, United States
Moderate
21 white, healthy female volunteers 
aged 18-28 y, nonsmokers, inactive, 
no history of cardiovascular disease 
Intervention, n = 13; control, n= 8
Intervention.  Low-intensity resistance 
exercise training on Nautilus 30 min/d, 
3 d/wk for 6 wks 
Control. Not trained
Relative to controls, intervention asso-
ciated with 
1.  no significant change in SBP
2.  no significant change in DBP
Duncan et al 1991 (31) 
Texas, United States
Moderate
3 mixed-race, healthy women aged 
20-0 y, nonsmokers, sedentary, “light 
or nondrinkers” 
Intervention, n = 3; control, n = 10
Intervention. Aerobic walking (n = 13), 
brisk walking (n = 12), or strolling (n = 
18)  .8 km,  d/wk for 2 wks 
Intensity. Aerobic walkers, 8.0 km/h; 
brisk walkers, 6. km/h; strollers, .8 
km/h
Control. Sedentary
Relative to controls, intervention asso-
ciated with 
1.  no significant change in seated 
blood pressure
2.  no significant change in TC
3.  no significant change in LDL-C
.  no significant change in HDL-C
.  no significant change in TG
Edin et al 1990 (32) 
Minnesota, United States
Moderate
1 healthy, nonpregnant women aged 
18-0 y, sedentary, nonsmokers with 
body weight within 80%-120% of stan-
dard body weight for height range 
Intervention, n = 10; control, n = 
Intervention. Aerobic exercise on tram-
poline 30 min,  d/wk for 11 wks 
Intensity. Training heart rate zone of 
0%-8% of maximal heart rate
Control. Sedentary
Relative to controls, intervention asso-
ciated with 
1.  no significant change in TC
2.  no significant change in HDL-C
3.  no significant change in TG
Oluseye et al 1990 (3) 
Ibadan, Nigeria
Moderate
2 sedentary Nigerian women, aged 
20-0 y 
Intervention, n = 30; control, n = 12
Intervention. Interval Aerobic Training 
Protocol (ITP) (n = 1) or Continuous 
Aerobic Training Protocol (CTP) (n = 1) 
0 min, 3 d/wk for 12 wks 
Intensity. Progressive 6%-9% of 
maximal heart rate with increases of 
% every 2 wks
Control. Sedentary
Relative to controls, interventions asso-
ciated with 
1.  decreased SBP
2.  decreased DBP
 
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; SBP, systolic blood 
pressure; DBP, diastolic blood pressure. 
a Quality ratings based on ECRI Institute 2-item validated instrument (20). 
b Number of subjects limited to those who completed the study. 
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Table 4. Selected Characteristics of Randomized Controlled Trials Examining Cardiovascular Effects of Diet and Exercise
Study, Setting, and 
Qualitya Study Populationb Intervention Results
Esposito et al 2003 
(39) 
Naples, Italy
High
120 premenopausal, sedentary, obese, 
nonpregnant women aged 20-6 y 
recruited from the outpatient department 
for weight loss of the teaching hospital. 
Exclusion criteria: dieting within previ-
ous 6 mos, type 2 diabetes or impaired 
glucose tolerance, hypertension, cardio-
vascular disease, psychological problems, 
alcohol abuse, smokers, and any medica-
tion use 
Intervention, n = 60; control, n = 60
Intervention. Individual counseling on 
increasing physical activity for 2 y; small 
group sessions on reducing dietary 
calories, personal goal setting, and self-
monitoring 
Intensity. Monthly sessions with a nutri-
tionist and exercise trainer for 12 mos, 
bimonthly for 12 mos
Control. Monthly group education ses-
sions
Relative to controls, intervention associ-
ated with 
1.  decreased SBP
2.  decreased DBP
3.  decreased TG
.  increased HDL-C
.  no significant change in TC
Blood pressure and cholesterol were 
secondary outcomes of the study; primary 
outcomes were inflammatory markers.
No adjustments were made for multiple 
comparisons.
Janssen et al 2002 
(36) 
Ontario, Canada
Moderate
38 premenopausal, upper-body obese, 
women with stable weight in 6 mos 
before study, taking no medications, with 
regular menses 
Mean age by group: diet and aerobics = 
3. y; diet and resistance = 3.8 y; diet 
only = 0.1 y
Intervention, n = 2; control, n = 13
Intervention. Weight maintenance diet for 
2 wks before pretreatment testing 
Diet and aerobics (DA) (n = 11); diet and 
resistance (DR) (n = 1); weight reduction 
diet for 16 wks
Intensity. Diet = 1000 kcal deficit diet; DA 
= 1-60 min sessions of aerobic exercise 
for  d/wk; DR = -10 min cycling and 
30 min sessions of resistance exercise 
3 d/wk
Control. Diet only
Relative to controls, intervention associ-
ated with 
1.  no significant change in TC
2.  no significant change in LDL-C
3.  no significant change in HDL-C
.  no significant change in TG
Fogelholm et al 
2000 (0)
UKK Institute, 
Tampere, Finland
Moderate
 premenopausal, healthy, sedentary 
female volunteers aged 30- y with 
body mass index 30- kg/m2 and stable 
weight over previous 3 months, nonbinge-
ing, not taking medication other than 
birth control, and not pregnant, lactating, 
or smoker 
Intervention, n = ; control, n = 2
Intervention. Twelve wks weight reduction 
diet followed by maintenance program for 
0 wks with weekly small group meetings 
and random assignment to walk-1 (n = 
2), walk-2 (n = 23), or control (n = 2); 
unsupervised 2-year follow-up 
Intensity. Walk-1 average 2-3 h weekly; 
walk-2 group average -6 h weekly
Control. Diet counseling with no change in 
exercise during maintenance program
Relative to controls, interventions associ-
ated with 
1.  no significant change in TC
2.  no significant change in HDL-C
3.  no significant change in TG
.  no significant change in SBP
.  no significant change in DBP
Blood pressure and cholesterol were 
secondary outcomes of the study; primary 
outcomes were body weight, fat mass, 
and waist circumference.
 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol. 
a Quality ratings based on ECRI Institute 2-item validated instrument (20). 
b Number of subjects limited to those who completed the study.
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Study, Setting, and 
Qualitya Study Populationb Intervention Results
Ågren et al 1991 
(3) 
University setting in 
Finland
Low
99 healthy female students (age not 
specified) 
Intervention, n = 6; control, n = 23
Intervention. Fish diet (n = 22), exercise 
(n = 2), or fish diet and exercise (n = 2) 
for 1 wks 
Intensity. Fish diet: offered meal contain-
ing 10g fish for  d/wk but uptake was 
3. d/wk; aerobic exercise: advised to 
obtain 30 min moderate intensity aerobic 
activity ≥3 times/wk but uptake was 1.3 
times/wk
Fish diet and aerobic exercise: as 
described above
Relative to controls, fish diet and exercise 
interventions associated with 
1.  decreased TG
2.  no significant change in TC
3.  no significant change in LDL-C
.  no significant change in HDL-C
Wood et al 1991 
(38) 
Stanford University, 
Palo Alto, California, 
USA
Moderate
112 healthy, sedentary, moderately over-
weight, nonsmoking, female volunteers 
aged 2-9 y, consuming < alcoholic 
drinks/d, not taking medication that could 
affect blood pressure or cholesterol, not 
lactating, pregnant, or taking oral contra-
ceptives in past 6 mos, and not planning 
pregnancy in next 2 years 
Intervention, n = 3; control, n = 39
Intervention. Diet-only (n = 31) or diet and 
exercise (n = 2) 
Intensity. Daily diet consisting of % car-
bohydrates and 30% fat with ≤10% satu-
rated fat and ≤300 mg cholesterol; week-
ly group sessions for 3 mos followed by 
every other week for 3 mos and monthly 
for 6 mos; supervised progressive aero-
bic exercise: brisk walking and jogging 3 
d/wk at 2 min per session increasing to 
 min per sessions by th month
Control. Asked to maintain usual diet and 
exercise habits
Relative to controls interventions associ-
ated with 
1.  decreased TC
2.  decreased LDL-C
3.  decreased TG
.  decreased SBP
.  decreased DBP
6.  no significant change in HDL-C
Relative to diet only group, diet and exer-
cise associated with increased HDL-C
 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; 
LDL-C, low-density lipoprotein cholesterol. 
a Quality ratings based on ECRI Institute 2-item validated instrument (20). 
b Number of subjects limited to those who completed the study.
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Table 5. National Blood Pressure and Cholesterol Screening Guidelines for Diagnosing Hypertension and Dyslipidemia in Women
Developer and Year Who and When to Screen Risk Factors Diagnostic Criteria
Hypertension
American Academy of Family 
Physicians (AAFP) (2) 2011
WHO: Women aged ≥18 y 
References US Preventive Services 
Task Force (USPSTF) 
WHEN: Healthy and at-risk adults: not 
stated but refers to JNC
References USPSTF
Smoking, diabetes, abnormal blood 
lipid values, older age, sex, sedentary 
lifestyle, and obesity
References USPSTF
SBP ≥140 mm Hg and/or  DBP ≥90 
mm Hg
≥2 elevated readings obtained on ≥2 
visits over a period of 1 to several 
weeks
American College of 
Obstetricians and 
Gynecologists (ACOG) (62) 
200
WHO: Women aged ≥18 y 
WHEN: Healthy and at-risk adults: not 
stated
African American, older age, prehyper-
tension, family history of hypertension, 
lifestyle factors associated with hyper-
tension
See criteria used by the National Heart, 
Lung, and Blood Institute (NHLBI) Joint 
National Committee on Prevention, 
Detection, Evaluation, and Treatment 
of High Blood Pressure (JNC)
American Heart Association 
(AHA) (3) 2011
WHO: Women aged ≥20 y 
WHEN: Healthy and at-risk adults: not 
stated, but refers to JNC
High risk: CHD, cerebrovascular dis-
ease, PAD, abdominal aortic aneurysm, 
end-stage or chronic renal disease, 
diabetes mellitus, 10-y Framingham 
global risk >20% 
At risk: cigarette smoking, prehyper-
tension, dyslipidemia, obesity, poor 
diet, physical inactivity, obesity, family 
history of premature CVD, metabolic 
syndrome, hypertension, dyslipid-
emia, evidence of vascular disease, 
subclinical atherosclerosis, metabolic 
syndrome, poor exercise capacity, sys-
temic autoimmune collagen-vascular 
disease, history of preeclampsia, gesta-
tional diabetes, or pregnancy-induced 
hypertension
SBP ≥140 mm Hg or DBP ≥90 mm Hg, 
or SBP ≥130 mm Hg or DBP ≥80 mm 
Hg if chronic kidney disease or diabe-
tes is present
Institute for Clinical Systems 
Improvement (ICSI) (,) 
2008, 2009
WHO: Average-risk, asymptomatic 
women aged ≥18 y
WHEN: Healthy adults: every 2 years
At-risk adults: prehypertension, 1 y; 
stage 1 hypertension, 2 mos; stage 2 
hypertension, within 1 mo
Hypertension, age, diabetes mellitus, 
elevated LDL-C, low HDL-C, estimated 
GFR <60 mL/min, microalbuminuria, 
family history of premature CVD, obe-
sity, physical inactivity, tobacco use, 
target organ damage to heart, brain, 
chronic kidney disease, PAD, or reti-
nopathy
Prehypertension: 
SBP = 120-139 mm Hg or DBP = 80-
89 mm Hg
Stage 1 hypertension:
SBP ≥140-159 mm Hg or, DBP ≥90-99 
mm Hg
Stage 2 hypertension:
SBP ≥160 mm Hg or, DBP ≥100 mm 
Hg
Initial visit plus 2 follow-up visits, each 
including 2 measures per visit
 
Abbreviations: NHLBI, National Heart, Lung, and Blood Institute; JNC , the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; AAFP, American Academy of Family Physicians; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; 
PAD, peripheral artery disease; CVD, cardiovascular disease; PAD, peripherial artery disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; GFR, glomerular filtration rate; TG, triglycerides; TC, total cholesterol.
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Developer and Year Who and When to Screen Risk Factors Diagnostic Criteria
NHLBI JNC (1) 2003 WHO: Adult women 
WHEN: Healthy adults: every 2 y
At-risk adults: prehypertension, 1 y; 
stage 1 hypertension, 2 mos; stage 
2 hypertension, within 1 mo, or if 
SBP ≥180 mm Hg or DBP ≥110 mm 
Hg, treat immediately or within 1 wk 
depending on clinical situation and 
complications
Hypertension, older age, diabetes mel-
litus, elevated LDL-C or total choles-
terol or low HDL-C, estimated GFR <60 
mL/min, family history of premature 
CVD, microalbuminuria, obesity, physi-
cal inactivity, tobacco usage, target 
organ damage to heart, brain, chronic 
kidney disease, PAD, or retinopathy
Prehypertension: 
SBP = 120-139 mm Hg or DBP = 80-
89 mm Hg 
Stage 1 hypertension, SBP ≥140 mm 
Hg or DBP ≥90 mm Hg
Stage 2 hypertension, SBP ≥160 mm 
Hg or DBP ≥100 mm Hg
Average of ≥2 seated blood pressure 
measurements per visit on ≥2 office 
visits
US Preventive Services Task 
Force (USPSTF) (6) 200
WHO: Women aged ≥18 y without 
known hypertension
WHEN: Healthy and at-risk adults: not 
stated but refers to JNC
Smoking, diabetes, abnormal blood 
lipid values, age, sex, sedentary life-
style, and obesity
Initial visit ≥2 follow-up visits within a 
few weeks to 1 mo, each including 2 
measures per visit
Veterans Health 
Administration (VHA) () 
200, revised 200
WHO: Women aged ≥17 y 
WHEN: Healthy adults: annually
At-risk adults: stage 1 hypertension, 2 
mos; stage 2 hypertension, within 1 mo
Tobacco use, dyslipidemia, diabetes 
mellitus, obesity, physical inactivity, 
microalbuminuria or estimated GFR 
<60 mL/min, age (>6 y for women), 
family history of CVD for women young-
er than 6 or men younger than 
Stage 1 hypertension, SBP ≥140 mm 
Hg or DBP ≥90 mm Hg 
Stage 2 hypertension, SBP ≥160 mm 
Hg or DBP ≥100 mm Hg
2 separate visits within 1-2 mo or 
sooner, each including ≥2 measures 
per visit
Dyslipidemia
AAFP (2) 2011 WHO: At-risk women aged 20- y 
References USPSTF.
WHEN: Healthy adults: No recommen-
dation
At-risk adults: Uncertain; reasonable 
option is at least once every  years, 
shorter intervals for people who have 
lipid levels close to those warranting 
therapy, longer intervals for those with 
repeatedly normal lipid levels
See USPSTF See USPSTF
ACOG (62) 200 WHO: Women aged ≥45 y and younger 
women with risk factors 
WHEN: Healthy and at-risk adults: not 
stated but refers to Adult Treatment 
Panel III (ATP III)
Presence of CHD, diabetes, other clini-
cal forms of atherosclerotic disease, 
cigarette smoking, hypertension, low 
HDL-C, family history of premature 
CHD, and older age
Recommends fasting and no exercise, 
tobacco use, or caffeine before mea-
surement 
Refers to ATP III
 
Abbreviations: NHLBI, National Heart, Lung, and Blood Institute; JNC , the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; AAFP, American Academy of Family Physicians; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; 
PAD, peripheral artery disease; CVD, cardiovascular disease; PAD, peripherial artery disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; GFR, glomerular filtration rate; TG, triglycerides; TC, total cholesterol.
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Developer and Year Who and When to Screen Risk Factors Diagnostic Criteria
AHA (3) 2011 WHO: Women aged ≥20 y 
WHEN: Healthy and at-risk adults: no 
recommendation
High risk: CHD, CVD, PAD, abdominal 
aortic aneurysm, end-stage or chronic 
renal disease, diabetes mellitus, 10-y 
Framingham global risk of ≥10% 
At risk: cigarette smoking, prehyperten-
sion, dyslipidemia, obesity, poor diet, 
physical inactivity, family history of 
premature CVD, metabolic syndrome, 
evidence of subclinical atherosclero-
sis, poor exercise capacity, systemic 
autoimmune collagen-vascular disease, 
history of preeclampsia, gestational 
diabetes, or pregnancy-induced hyper-
tension
LDL-C ≥100 mg/dL 
HDL-C ≤50 mg/dL
TG ≥150 mg/dL
Non-HDL-C ≥130 mg/dL
ICSI (,63) 2009 WHO: Women aged ≥45 y and at-risk 
women aged 20- y 
WHEN: Healthy adults: every  y
At-risk adults: every 3-12 mos
First-degree relatives with total cho-
lesterol >300 mg/dL or history of 
premature CHD; personal history of 
CHD, CVD, peripheral vascular disease, 
diabetes mellitus, metabolic syndrome, 
current dyslipidemia 
Also refers to ATP III definitions of high 
risk
TC ≥200 mg/dL 
LDL-C ≥130 mg/dL
TG ≥200 mg/dL
HDL-C <0 mg/dL
NHLBI, National Cholesterol 
Education Program, ATP III 
(8) 2002
WHO: Women aged ≥20 y 
WHEN: Healthy adults: at least once 
every  y
At-risk adults: more frequent measure-
ments are required for persons with 
multiple risk factors or, in those with 
0-1 risk factor, if the LDL-C level is only 
slightly below the goal level
High risk: CHD, or CHD risk equivalent 
including PAD, carotid artery disease, 
abdominal aortic aneurysm, type 2 
diabetes, 10-y Framingham global risk 
of >20% due to multiple risk factors 
including cigarette smoking, hyperten-
sion, low HDL-C, family history of pre-
mature CHD, aged ≥55 y for women
Optimal/Desirable: TC <200 mg/dL, 
LDL-C <100 mg/dL, HDL-C ≥60 mg/dL, 
TG <10 mg/dL 
Above optimal: LDL-C = 100-129 
mg/dL
Borderline high: TC = 200-239 mg/dL, 
LDL-C = 130-19 mg/dL, TG = 10-
199 mg/dL
High: TC ≥240 mg/dL, LDL-C = 160-
189 mg/dL, HDL-C <0 mg/dL, TG = 
200-99 mg/dL
Very high: LDL-C ≥190 mg/dL, TG 
≥500 mg/dL
 
Abbreviations: NHLBI, National Heart, Lung, and Blood Institute; JNC , the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; AAFP, American Academy of Family Physicians; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; 
PAD, peripheral artery disease; CVD, cardiovascular disease; PAD, peripherial artery disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; GFR, glomerular filtration rate; TG, triglycerides; TC, total cholesterol.
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Developer and Year Who and When to Screen Risk Factors Diagnostic Criteria
USPSTF (6) 2008 WHO: At-risk women aged 20- y 
WHEN: Healthy adults: no recommen-
dation
At-risk adults: uncertain; reasonable 
options include every  y, shorter inter-
vals for people who have lipid levels 
close to those warranting therapy, 
and longer intervals for those not at 
increased risk with repeatedly normal 
lipid levels
Diabetes, previous personal history of 
CHD or noncoronary atherosclerosis, 
family history of CVD before age 0 
in male relatives or age 60 in female 
relatives, tobacco use, hypertension, 
obesity
TC and HDL-C (fasting or nonfasting)
Confirm abnormal screening test 
results with a repeated sample on a 
separate occasion, and the average 
of both results should be used for risk 
assessment
VHA (6) 2006 WHO: All adult women aged ≥45 y and 
adult women <45 y with ≥1 risk factors 
WHEN: Healthy adults: every  years
At-risk adults: more often if family his-
tory of premature CVD exists
Older age, family history of premature 
CVD, hypertension, or under treatment 
for hypertension, smoking, diabetes 
mellitus, abdominal obesity
Fasting lipid profile including TC ≥240 
mg/dL, HDL-C <0 mg/dL, TG >200 
mg/dL, LDL-C ≥130 mg/dL, if calcu-
lated but consider direct measurement 
of LDL-C if TG >00 mg/dL
 
Abbreviations: NHLBI, National Heart, Lung, and Blood Institute; JNC , the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; AAFP, American Academy of Family Physicians; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHD, coronary heart disease; 
PAD, peripheral artery disease; CVD, cardiovascular disease; PAD, peripherial artery disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; GFR, glomerular filtration rate; TG, triglycerides; TC, total cholesterol.
Table 5. (continued) National Blood Pressure and Cholesterol Screening Guidelines for Diagnosing Hypertension and Dyslipidemia in 
Women